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ABSTRACT  
STUDY DESIGN: Retrospective Cohort 
OBJECTIVE To characterize one surgeon’s experience over a 10-year period 
using rhBMP-2 in the disc space for minimally invasive transforaminal lumbar 
interbody fusion (MIS TLIF). 
SUMMARY OF BACKGROUND DATA: MIS TLIF has been utilized as a 
technique for decreasing patients’ immediate post-operative pain, decreasing 
blood loss, and shortened hospital stays. Effectiveness and complications of 
rhBMP-2’s use in the disc space is limited due to its off-label status.  
METHODS: Retrospective analysis of consecutive MIS TLIFs performed by 
senior author between 2004-2014. rhBMP-2 was used in the disc space in all 
cases. Patients were stratified based on the dose of rhBMP-2 utilized. Patients 
had 9-12 month CT scan to evaluate for bony fusion and continued follow-up 
for 18 months.  
RESULTS: A total of 688 patients underwent a MIS TLIF.  A medium kit of 
rhBMP-2 was utilized in 97 patients, and small kit was used in 591 patients. 
Fusion rate was 97.9% and this was not different between the two groups with 
96/97 patients fusing in the medium kit group and 577/591 patients fusing in the 
small kit group. Five patients taken back to the operating room for symptomatic 
pseudoarthrosis, four re-operated for bony hyperostosis, and ten radiographic 
pseudoarthroses that did not require re-operation. A statistically significant 
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difference in the rate of foraminal hyperostosis was found when using a medium 
sized kit of rhBMP-2 was 4.12% (4/97 patients), compared to a small kit (0/591 
patients, p = 0.0004)  
CONCLUSIONS: Utilization of rhBMP-2 in an MIS TLIF leads to high fusion 
rate (97.9%), with an acceptable complication profile. The development of 
foraminal hyperostosis is a rare complication that only affected 0.6% of patients, 
and appears to be a dose related complication, as this complication was 
eliminated when a lower dose of rhBMP-2 was utilized.
 4 
KEY WORDS: TLIF; lumbar fusion; minimally invasive; Bone morphogenic protein; 
neuronavigation; O-arm 
EVIDENCE: Level 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5 
Introduction 
Minimally invasive spine (MIS) techniques have gained widespread popularity and 
acceptance in the recent years due to minimizing soft tissue dissection, shorter hospital 
stays, and shorter recovery period.
1-11 Achieving interbody fusion has been challenging for 
some surgeons, partially due to the paucity of bony surfaces that are exposed and 
decorticated.  When performing interbody fusion through a minimally invasive approach, 
that degree of difficulty is even higher.  Achieving successful interbody fusion can be 
challenging and as a result, biologic agents are often considered to augment fusions. 
Recombinant bone morphogenetic protein-2 (rhBMP-2) has been demonstrated to 
lead to high levels of fusions, however, its use has decreased significantly in recent years 
in large part due to the identification of under-reported complications in the initial industry 
sponsored studies.12–14 Over the past decade, there has been concern with the use of 
rhBMP-2 leading to seroma formation, osteolysis, bony hyperostosis and even possibly 
cancer.15,16 While the risk of cancer has not been definitely proven or refuted, there is little 
doubt that the other complications can occur; however, the prevalence of these 
complications is unclear, and may be dependent on the dose and the surgical technique in 
which rhBMP-2 is utilized. With regards to its use in an MIS TLIF, a potentially 
concerning complication is the development of hyperostosis leading to recurrent foraminal 
stenosis. There have been several reports of bony hyperostosis requiring re-operation after 
an MIS TLIF utilizing rhBMP-2, but these reports are deficient in incidence, dosing, and 
technique in relation to the use of rhBMP-2.17,18 The purpose of this study is two-fold. 
First, is to determine the fusion rates as well as the rate of rhBMP-2 associated 
complications in a large series of patients who underwent an MIS TLIF utilizing rhBMP-
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2.  The second purpose is to determine if the dose of rhBMP-2 affects the fusion and 
complication rate.  
 
Materials and Methods 
Study Design  
Institutional review board approval was obtained for this study, and study was performed 
without financial assistance. We performed a retrospective analysis of 688 consecutive 
patients undergoing a 1 and 2 level TLIF procedure from January 2004 to January 2014. 
The chart was then mined for patients undergoing minimally invasive vs open procedures. 
All patients had demographic information recorded including, age, gender, BMI, smoking 
status, diabetic status, and bone density performed and these are listed in Table 1. All 
patients were followed for a minimum of 18 months with standard post operative imaging 
with at least 1 CT scan to assess for screw position and fusion at 9–12 months after 
surgery. Complications including seroma formation, infection and osteolysis requiring 
reoperation were also investigated. It should be noted that technique was changed from the 
conventional fluoroscopic technique to the fully navigated technique in 2006. This change 
in technique was purely for percutaneous placement of intrumentation and did not change 
fusion techniques.  
All MIS cases were performed by the senior author (JPM), a fellowship-trained 
spine surgeon who has been practicing since 2004. rhBMP-2 dosages, pseudoarthroses, 
hyperostosis requiring re-operation, all re-operations for any reason, seromas, spinal fluid 
leaks, dural tears, and hardware failures were recorded. Patients who had surgery prior to 
2006 had a medium size kit, which consists of 8.4 mg of rhBMP-2 used at each level, and 
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patients after 2006 had a small kit containing 4.2 mg of rhBMP-2 used at each level. 
Besides the change in kit size, there were no other changes to the technique. Once all the 
data was collected, we compared the two groups and assested for any statistical difference 
using a T-test.  
 
Description of the technique fully navigated technique: 
This fully navigated TLIF is described using O-arm imaging, Sextant or Voyager 
percutaneous screw system, and METRx tubular retractor system (Medtronic; Memphis, 
TN). We position the patient on Jackson table with a chest pad and four post-hip pads. 
The patient is then prepped and draped very wide and low making sure to drape in 
the iliac crest. The posterior superior iliac spine is palpated and the percutaneous pin is 
placed with the arrow on the pin facing towards the feet. The pin is driven into the 
posterior superior iliac spine in a medial to lateral trajectory allowing the reference arc to 
be placed facing the feet and leaning towards the midline of the sacrum. After the 
reference arc is placed, the O-arm image is obtained. Care should be taken not to bump the 
reference arc during acquisition of pictures or at any point thereafter. 
Skin incision is planned based on navigation, and awl-tip navigated tap is used to 
tap the pedicles and measure the screw size based on the navigated image, and the plans are 
saved. The contralateral screws to the side of the TLIF are inserted, but the screw holes are 
only tapped on the ipsilateral side and plans are saved. These screws will be placed after 
the decompression and interbody work has been completed. The tubular retractor is then 
docked and the facet is removed using a combination of high-speed drill, kerrisons, or 
osteotomes, depending on the surgeon’s preference.  At our institution, we have favored 
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utilizing the drill and kerrisons for bone removal.  The bone dust collector is utilized to 
capture the bone removed during drilling, and a funnel is packed with this bone in order to 
deliver it into the disc space.  
Once the decompression has been completed, the disc space is prepped thoroughly 
making sure endplates are exposed. The small kit of rhBMP-2 sponges are wrapped 
around the harvested local autograft and passed through the annulotomy defect to the far 
side of the disc space. The rest of the harvested autograft is then packed into the disc space  
pushing the BMP sponges even further away from the annulotomy. The bone dust funnel 
is then inserted into the disc space, and the space is filled as much as possible. A peek 
cage full of bone is then inserted in the standard fashion placing it to the anterior margin of 
the intervertebral space. The procedure is finished with placing the ipsilateral screws and 
passing the rods down into the screw heads, followed by compression and set screw final 
tightening. Closure includes the fascial layer, followed by the subcutaneous tissues, and 
then the dermal layer. 
 
Results 
From the years of 2004–2014, 688 patients underwent an MIS TLIF. Ninety-seven 
patients have a medium kit of rhBMP-2 utilized and 591 patients having a small kit used. 
Additionally, 226 patients underwent 2 levels of fusion and 462 underwent a single level. 
Demographic data is listed in Tables 1 and 2, showing a good portion of these patients 
having barriers to surgery and especially fusion such as factors such as obesity, 
osteopenia, diabetes, and active smoking. Importantly there was no significant difference 
in the groups between patients undergoing a 1 and 2 level fusion, or those who underwent 
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a fusion utilizing a medium or a small kit of rhBMP-2.  
The levels fused are listed in Table 3. Between the two groups, 914 levels were 
fused, and 3,204 screws were inserted. The majority of the levels as were fused at L4/5 
and L5/S1 for both single and 2 level fusion, comprising 74% percent of all fusion levels.  
During the 15-24 months these patients were followed, there were five patients 
taken back to the operating room for symptomatic pseudoarthrosis, four were re-operated 
for bony hyperostosis, and nine stable radiographic pseudoarthroses that did not require re-
operation were found as shown in Table 4. There was no more than 1 level of hyperostosis 
or pseudarthrosis per patient. The stable pseudarthrosiss were both asymptomatic with 
regards to back and leg pain, and were radiographically stable without evidence of 
movement on flexion extension radiographs or evidence of hardware radiolucency on 
computed tomography scan.  The diagnosis of stable pseudoarthroses is made due to the 
fact that there is a paucity of bridging bone within the disc space visible on CT scan 
without any sign of instability or hardware loosening. 
The four patients re-operated for bony hyperostosis were patients done during the 
period between 2004 and 2007 where medium kits of rhBMP-2 were still being used in the 
disc space. The overall rate when using a medium sized kit of rhBMP-2 was 4.12% (4/97 
patients), and this was significantly higher than the 0% (0/591 patients) rate of 
hyperostosis when a small kit was used (p = 0.0004). Importantly, even in the patients who 
did develop hyperostosis, no new deficits or symptomatic spinal fluid leaks were 
developed secondary to these re-operations. In the entire cohort, there were also no re-
operations for seroma formation or osteolysis irrespective of the dose of rhBMP-2 utilized.  
With regards to the fusion rate, a total of 914 levels were fused in 688 patients. Out 
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of the 914 levels fused, five levels required re-operation for non-union (0.7%), and there 
were 10 total levels of stable pseudoarthrosis that were found on routine CT scan. This is a 
2.1% pseudoarthrosis rate with respect to patients and 1.6% pseudoarthrosis rate with 
respect to levels fused overall. When  comparing patients who underwent surgery utilizing 
medium kit and a small kit of rhBMP-2, no difference was identified in the fusion rate of 
the levels [96/97 vs 577/591, p = 0.40 CI (-3.34 to 3.12), respectively]. The fusion rates 
are similar between the two groups but small kits did not cause any hyperostosis.  
 
 
Discussion 
This is one of the largest series of MIS TLIFs where rhBMP-2 was used 
universally used at every disc level to aid in fusion, and the study finds that the use of 
rhBMP-2 leads to a fusion rate of 98% with an acceptable complication rate. While there 
were no patients diagnosed with seroma or osteolysis, four patients were found to have 
foraminal hypersostosis. Importantly, this appears to be a dose related complication as the 
rate was significantly less (p = 0.0004) in patients who had a small kit of rhBMP-2 utilize.  
The first point of discussion is the fusion rate. The percentage of smokers and 
patients with osteopenia in this series would suggest a higher rate of pseudoarthrosis than 
occurred. Even when taking into comparison the stable non-union patients, the rate of 
pseudoarthrosis was 2.1%, a number that is on par or exceeds most open TLIF series in the 
literature as is the reoperation rate of 0.7%.1, 11, 19, 21 This finding is critical, because while 
the ability to adequately prepare the interbody space for a fusion has been demonstrated to 
be similar in open versus MIS techniques,22 an open TLIF allows for both an interbody 
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fusion as well as a posterolateral fusion. The results of this study suggest that when 
rhBMP-2 is utilized in an MIS TLIF, the posterolateral fusion is not necessary. Several 
studies report open lumbar fusion techniques with rhBMP-2, citing pseudoarthrosis rates 
from 0.9%-3.5%. 23–25  There are fewer studies specifically looking at MIS technique, 
however Singh reports a pseudoarthrosis rate of 6.8%.26 Another critically important 
finding in this study is that no difference was identified in the fusion rate between patients 
who had a medium or a small kit of rhBMP-2 utilized. Because there is an obvious 
difference in cost, and likely a dose dependent rate of complication, this finding 
demonstrates that at most, a small kit of rhBMP-2 is needed per level, and it is possible that 
an even smaller dose may be equally efficacious.  
What is more controversial than the fusion rate, however, is the complication profile 
associated with use of rhBMP-2 in the disc space from the posterior approach. From the 
circulating case series,18 it would seem that exuberant hyperostosis requiring reoperation is a 
common complication and should deter surgeons from its use. Although case reports are 
present in the literature, large series such as this one are limited, which makes quantifying 
the frequency of these complications difficult. In this series, 0.6% of patients needed a return 
to OR from complications related to bony overgrowth. Before and after the re-operations, 
there were no new neurologic deficits that were observed. When the numbers are broken 
down even further, 97 patients received medium kits of rhBMP-2 in their interspace and 591 
received a small kit. Out of the 97 patients receiving the medium sized kit, 4 returned to the 
OR. Of the 591 consecutive patients receiving the small kit, there were no instances of bony 
overgrowth requiring re-operation. The results of this study were similar to those by Singh et 
al. 26 that reviewed 573 patients undergoing an MIS TLIF utilizing rhBMP-2. They reported 
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10 patients (1.75%) developed foraminal hyperostosis. Rihn reported a similar rate of bony 
hyperostosis of 2%.27 Interestingly, in Singh’s study, nine of the patients who developed 
formainal overgrowth had a small kit of rhBMP-2 used. So while the results of our study 
suggest that foraminal hyperostosis is a dose related complication, when comparing the 
current study results to the results of Singh, it is possible that this complication can also be 
affected by surgical technique.   
Even when taking into account the re-operation for bony overgrowth, the re-
operation rate for fusion related complications in this series was 1%, which most surgeons 
would argue is an acceptable number.7,19, 21, 28 What’s more, there were no re-operations 
secondary to seroma formation or osteolysis causing instability, suggesting that these 
phenomena may also be seen at doses higher than what was used or with a different 
technique. Kahn et al compared rhBMP-2 to autograft and found high rates of seroma and 
radiculitis, however he has also recommended using smaller doses to reduce the rate of 
radiculitis, which he reported to be 8.4% in his series. 29 
There are limitations to this study that are inherent to the retrospective nature of 
the study. Specifically, while this is one of the largest studies to date on the fusion rate and 
complications when rhBMP-2 is utilized for an MIS TLIF, the study is unable to report on 
health related quality of life outcome metrics. Additionally, these are the results of a 
single, high-volume academic surgeon, and thus is inherent to the biases of a study 
associated with one surgeon.  Another potentially confounding factor is that the medium 
kit was used early in the surgeon’s career when his surgical skills were still early in the 
learning curve, and this could affect the complication rate that we are attributing to the 
higher dose of rhBMP-2. 
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Utilization of rhBMP-2 in an MIS TLIF leads to high fusion rate (98.2%), with an 
acceptable complication profile. The development of extraforaminal hyperostosis is a rare 
complication that only affected 0.6% of patients, and appears to be a dose related 
complication, as this complication was eliminated when a lower dose of rhBMP-2 was 
utilized.  
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Table 1: Patient demographics organized by number of levels performed MIS (%)   Single Level (%) Two Level (%) P-Value for significant difference Total Patients 462 226  Male 183 (40) 98(42) 0.61 Female 276 (60) 128 (58) 0.61 Age in yr (range) 24-87 36-70  Age in yr (mean) 57.7 54.3 0.71 BMI (range) 23.1-48.1 30.4-46.3  BMI (mean) 40.2 37.1 0.43 Diabetes 93 (20) 54 (24) 0.23 Smoking 71 (15) 31 (14) 0.73 Osteopenia 79 (17) 26 (12) 0.09  MIS = minimally invasive spine.                               
Table 2: 
Patient demographics organized by small and medium kit (%)  Medium Kit (%) Small Kit (%) P-Value for significant difference Total Patients 97 591  Male 40 (41) 256 (43) 0.71 Female 57 (59) 337 (57) 0.71 Age in yr (range) 24-87 35-81  Age in yr (mean) 56.8 57.8 0.85 BMI (range) 23.1-45.1 30.4-46.3  BMI (mean) 37.7 38.8 0.84 Diabetes 24 (25) 147 (25) 1.00 Smoking 17 (18) 82 (14) 0.30 Osteopenia 17 (18) 81 (14) 0.30 Single Level 76  391   Two Level 21 200                                
      Table 3: Number of levels and anatomic levels fused   Single Level Open Two Level Open Total Levels fused 462 452 Total Screws 1848 1356 L1/2 0 0 L2/3 42 40 L3/4 81 75 L4/5 193 155 L5/1 146 182                               
  
Table 4: Levels of pseudoarthrosis and hyperostosis needing revision broken down by level 
Number of levels 1 level 2 levels 
Patients 462 226 
Levels of pseudoarthrosis 1 4 
Levels of hyperostosis 4 0 
Medium kits used 84 13 
Small kits used 378 213 
Symptomatic Pseudoarthrosis levels  (medium) 0 0 
Hyperostosis levels  (medium) 4 0 
Symptomatic Pseudoarthrosis levels (small) 1 4 
Hyperostosis levels (small) 0 0 
Stable Pseudoarthrosis (medium) 0 1 
Stable Pseudoarthrosis  (small) 2 7 
Fusion (medium) 84 12 
Fusion (small) 375 202 
Fusion % (medium) 100% 92.3% 
Fusion % (small) 99.2% 94.8% 
           
